Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant zoster vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Shingrix is a non-live, recombinant subunit vaccine developed by GSK for the prevention of herpes zoster (shingles) and postherpetic neuralgia in adults. It consists of the Varicella Zoster Virus (VZV) glycoprotein E (gE) antigen produced in Chinese Hamster Ovary cells, combined with the AS01B adjuvant system. The AS01B adjuvant is a liposome-based system containing two immunostimulants: 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and QS-21. This combination is designed to enhance the antigen-specific cell-mediated immune response, which is critical for controlling the reactivation of VZV. The vaccine is typically administered as a two-dose series. The University of Wisconsin, Madison has been involved in clinical research evaluating the vaccine's safety and immunogenicity in specific populations, such as patients with inflammatory bowel disease (IBD) receiving biologic or JAK inhibitor therapies.
- Brand names
- Shingrix
- Other names
- Adjuvanted Recombinant Zoster VaccineShingles vaccine (recombinant, adjuvanted)
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on recombinant zoster vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant zoster vaccine.